Compare Ascendis Pharma A/S (ASND) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Global Payments Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Global Payments Inc trades at $76.09 (market cap $20.80B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.32% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GPN | |
|---|---|---|
Market Cap | $17.74B | $20.80B |
Sector | Health | Industrials |
52-Week High | $277.18 | $90.01 |
52-Week Low | $163.32 | $62.47 |
Enterprise Value | $18.11B | $38.52B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Global Payments (GPN) trades at $76.04, up 2.23% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid operating cash flow of $2.66B for 2025 and a gross profit margin of 67.34%, though net income margin turned negative at -7.97% for 2026. Recent developments include AI-powered POS launches and expansion of restaurant partnerships, driving positive analyst sentiment with a consensus price target of $81.56.
GPN presents a mixed outlook: upside exists from earnings momentum and strategic initiatives like the Worldpay integration, but risks include margin pressure, rising debt-to-asset ratio of 41.57%, and intense fintech competition. The stock's current valuation at a P/E of 27.96 appears reasonable relative to growth prospects, yet investors must weigh execution risks against potential rewards in a competitive payments landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
